Himax Technologies, Inc. (HIMX)

Revance Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Revance Therapeutics stock has a target of 15, which predicts a 73.41% increase from the current stock price of 8.65.

Price Target: $15.00 (+73.41%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$15	$15	$15	$15
Change	+73.41%	+73.41%	+73.41%	+73.41%

* Price targets were last updated on Dec 13, 2024.

Analyst Ratings

According to 1 stock analyst, the rating for Revance Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	0	0	0	0	0	0
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Tristan Gerra Baird	Baird	Buy Maintains $7 → $15	Buy	Maintains	$7 → $15	+73.41%	Dec 13, 2024
Jerry Su Credit Suisse	Credit Suisse	Hold → Buy Upgrades $7 → $8	Hold → Buy	Upgrades	$7 → $8	-7.51%	Aug 11, 2023
Jerry Su Credit Suisse	Credit Suisse	Buy → Hold Downgrades $7	Buy → Hold	Downgrades	$7	-19.08%	Jul 14, 2022
Jerry Su Credit Suisse	Credit Suisse	Buy Maintains $18 → $14	Buy	Maintains	$18 → $14	+59.54%	May 16, 2022
Donnie Teng Nomura Instinet	Nomura Instinet	Strong Buy → Hold Downgrades $11	Strong Buy → Hold	Downgrades	$11	+27.17%	Apr 7, 2022

More Analyst Ratings

Financial Forecast

Revenue This Year

929.44M

Increased by 2.50%

from 906.80M

Revenue Next Year

1.02B

Increased by 9.42%

from 929.44M

EPS This Year

0.46

Decreased by -0.07%

from 0.46

EPS Next Year

0.60

Increased by 30.65%

from 0.46

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	887.28M	1.55B	1.20B	945.43M	906.80M	929.44M	1.02B	1.02B
Revenue Growth	32.07%	74.36%	-22.35%	-21.30%	-4.09%	2.50%	9.42%	0.39%
EPS	0.27	2.50	1.36	0.28	0.46	0.46	0.60	0.66
EPS Growth	-	816.83%	-45.75%	-79.36%	62.96%	-0.07%	30.65%	10.45%
Forward PE	-	-	-	-	-	18.97	14.52	13.15
No. Analysts	-	-	-	-	-	7	7	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	1.1B	1.3B	1.1B
Avg	929.4M	1.0B	1.0B
Low	834.4M	874.2M	937.9M

Revenue Growth

Revenue Growth	2025	2026	2027
High	23.0%	37.8%	8.0%
Avg	2.5%	9.4%	0.4%
Low	-8.0%	-5.9%	-7.8%

EPS Forecast

EPS	2025	2026	2027
High	0.61	0.79	0.79
Avg	0.46	0.60	0.66
Low	0.31	0.41	0.53

EPS Growth

EPS Growth	2025	2026	2027
High	33.0%	74.1%	32.2%
Avg	-0.1%	30.6%	10.4%
Low	-31.3%	-9.7%	-11.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.